60d FRN - published 02NOV2020

jbell on DSKJLSW7X2PROD with NOTICES

Federal Register / Vol. 85, No. 212 / Monday, November 2, 2020 / Notices
Comment: FTC File No. P072108’’ on
your comment and on the envelope, and
mail your comment to the following
address: Federal Trade Commission,
Office of the Secretary, 600
Pennsylvania Avenue NW, Suite CC–
5610 (Annex J), Washington, DC 20580;
or deliver your comment to the
following address: Federal Trade
Commission, Office of the Secretary,
Constitution Center, 400 7th Street SW,
5th Floor, Suite 5610 (Annex J),
Washington, DC 20024. If possible,
submit your paper comment to the
Commission by courier or overnight
service.
Because your comment will become
publicly available at https://
www.regulations.gov, you are solely
responsible for making sure that your
comment does not include any sensitive
or confidential information. In
particular, your comment should not
include any sensitive personal
information, such as your or anyone
else’s Social Security number; date of
birth; driver’s license number or other
state identification number, or foreign
country equivalent; passport number;
financial account number; or credit or
debit card number. You are also solely
responsible for making sure that your
comment does not include any sensitive
health information, such as medical
records or other individually
identifiable health information. In
addition, your comment should not
include any ‘‘trade secret or any
commercial or financial information
which . . . . is privileged or
confidential’’ —as provided by Section
6(f) of the FTC Act, 15 U.S.C. 46(f), and
FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)
—including in particular competitively
sensitive information such as costs,
sales statistics, inventories, formulas,
patterns, devices, manufacturing
processes, or customer names.
Comments containing material for
which confidential treatment is
requested must be filed in paper form,
must be clearly labeled ‘‘Confidential,’’
and must comply with FTC Rule 4.9(c).
In particular, the written request for
confidential treatment that accompanies
the comment must include the factual
and legal basis for the request, and must
identify the specific portions of the
comment to be withheld from the public
record. See FTC Rule 4.9(c). Your
comment will be kept confidential only
if the General Counsel grants your
request in accordance with the law and
the public interest. Once your comment
has been posted publicly at
www.regulations.gov, we cannot redact
or remove your comment unless you
submit a confidentiality request that
meets the requirements for such

VerDate Sep<11>2014

20:55 Oct 30, 2020

Jkt 253001

treatment under FTC Rule 4.9(c), and
the General Counsel grants that request.
The FTC Act and other laws that the
Commission administers permit the
collection of public comments to
consider and use in this proceeding, as
appropriate. The Commission will
consider all timely and responsive
public comments that it receives on or
before January 4, 2021. For information
on the Commission’s privacy policy,
including routine uses permitted by the
Privacy Act, see https://www.ftc.gov/
site-information/privacy-policy.
Josephine Liu,
Assistant General Counsel for Legal Counsel.
[FR Doc. 2020–24094 Filed 10–30–20; 8:45 am]
BILLING CODE 6750–01–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60-Day–21–0696; Docket No. CDC–2020–
0111]

Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on a
proposed information collection project
titled National HIV Prevention Program
Monitoring and Evaluation (NHM&E).
NHM&E collects standardized HIV
prevention program evaluation data
from health departments and
community-based organizations (CBOs)
who receive federal funds for HIV
prevention activities.
DATES: CDC must receive written
comments on or before January 4, 2021.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0111 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
SUMMARY:

PO 00000

Frm 00022

Fmt 4703

Sfmt 4703

69333

Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger,
Information Collection Review Office,
Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7118; Email: omb@cdc.gov.
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:
1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.

E:\FR\FM\02NON1.SGM

02NON1

69334

Federal Register / Vol. 85, No. 212 / Monday, November 2, 2020 / Notices

Proposed Project
National HIV Prevention Program
Monitoring and Evaluation (NHM&E)
(OMB Control No. 0920–0696, Exp. 10/
31/2021)—Revision—National Center
for HIV/AIDS, Viral Hepatitis, STD, and
TB Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
CDC seeks to request a three-year
Office of Management and Budget
(OMB) approval to revise the previously
approved project and continue the
collection of standardized HIV
prevention program evaluation data
from health departments and
community-based organizations (CBOs)
who receive federal funds for HIV
prevention activities. Health department
grantees have the options to key-enter or
upload data to a CDC-provided webbased software application
(EvaluationWeb®). CBO grantees may
only key-enter data to the CDC-provided
web-based software application.

are providing services, what resources
are allocated to those services, to whom
services are being provided, and how
these efforts have contributed to a
reduction in HIV transmission; (2)
improve ease of reporting to better meet
these data needs; and (3) be accountable
to stakeholders by informing them of
HIV prevention activities and use of
funds in HIV prevention nationwide.
CDC HIV prevention program grantees
will collect, enter or upload, and report
agency-identifying information, budget
data, intervention information, and
client demographics and behavioral risk
characteristics with an estimate of
204,498 burden hours, representing no
change from the previously approved,
204,498 burden hours. Data collection
will include searching existing data
sources, gathering and maintaining data,
document compilation, review of data,
and data entry or upload into the webbased system. There are no additional
costs to respondents other than their
time.

This revision includes changes to the
data variables to adjust to the different
monitoring and evaluation needs of new
funding announcements without a
substantial change in burden.
The evaluation and reporting process
is necessary to ensure that CDC receives
standardized, accurate, thorough
evaluation data from both health
department and CBO grantees. For these
reasons, CDC developed standardized
NHM&E variables through extensive
consultation with representatives from
health departments, CBOs, and national
partners (e.g., The National Alliance of
State and Territorial AIDS Directors and
Urban Coalition of HIV/AIDS
Prevention Services).
CDC requires CBOs and health
departments who receive federal funds
for HIV prevention to report
nonidentifying, client-level and
aggregate level, standardized evaluation
data to: (1) Accurately determine the
extent to which HIV prevention efforts
are carried out, what types of agencies

ESTIMATED ANNUALIZED BURDEN HOURS
Average
burden per
response
(in hours)

Total burden
(in hours)

Form name

Health Departments ..........................
Community-based Organizations ......

Health Department Reporting ..........
Community-based Organization Reporting.

66
150

2
2

1,426.5
54

188,298
16,200

Total ...........................................

...........................................................

........................

........................

........................

204,498

Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–24231 Filed 10–30–20; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Awards Unsolicited Proposal; Catalog
of Federal Domestic Assistance
(CFDA) Number: 93.137 and 93.129
Office of Minority Health
(OMH) and Office of the Assistant
Secretary for Health, Department of
Health and Human Services.
ACTION: Notice of award of an
unsolicited request for funding to be
awarded as a single project through two
cooperative agreement awards to the
American Heart Association (AHA),
Dallas, Texas.
AGENCY:

jbell on DSKJLSW7X2PROD with NOTICES

Number of
responses per
respondent

Number of
respondents

Type of respondents

OMH announces the award of
a single-source award in response to an
unsolicited proposal from the American

SUMMARY:

VerDate Sep<11>2014

20:55 Oct 30, 2020

Jkt 253001

Heart Association, Dallas, Texas. The
proposal submitted was not solicited
either formally or informally by any
federal government official. The award
is comprised of two cooperative
agreements administered by OMH in
collaboration with HRSA.
FOR FURTHER INFORMATION CONTACT: Paul
Rodriguez at paul.rodriguez@hhs.gov or
by telephone at 240–453–8208.
SUPPLEMENTARY INFORMATION:
Recipient: American Heart
Association, Dallas, Texas.
Purpose of the Award: The Office of
Minority Health (OMH) will award a
cooperative agreement to AHA to
improve COVID-related health outcomes
for highly impacted racial and ethnic
minorities by addressing hypertension
as a key risk factor. In addition, OMH
will award a cooperative agreement to
AHA, on behalf of the Health Resources
and Services Administration (HRSA), to
provide technical assistance to HRSAfunded health centers to increase
provider and clinician engagement in
implementing evidence-based practices
(e.g., advanced self-measured blood

PO 00000

Frm 00023

Fmt 4703

Sfmt 4703

pressure technology) to increase the
number of adult patients with
controlled hypertension and reduce the
potential risk of COVID-related health
outcomes. The two cooperative
agreements will support a single
national project that is expected to
identify promising approaches/best
practices that combine new blood
pressure measurement technology,
lifestyle/behavioral modifications and
locally targeted media campaigns to
address uncontrolled, including
undiagnosed, high blood pressure in
racial and ethnic minority, American
Indian/Alaska Native and other
vulnerable populations, given the
association of hypertension with worse
COVID–19 health outcomes.
The project is expected to support
training and technical assistance to
support HRSA-funded health centers’
implementation of evidence-based
interventions that combine remote
blood pressure monitoring technology to
reduce disparities in uncontrolled and
undiagnosed high blood pressure among
medically underserved communities

E:\FR\FM\02NON1.SGM

02NON1